No Data
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $30 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $30 price target.
Cabaletta Bio's Promising Clinical Advancements and Stable Financial Outlook Merit a Buy Rating
William Blair Reaffirms Their Buy Rating on Cabaletta Bio (CABA)
NEXTracker Posts Upbeat Earnings, Joins Monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones gaining around 150 points on Wednesday.Shares of Nextracker Inc. (NASDAQ:NXT) rose sharply during Wednesday's session after the company reported better-than
Cabaletta Bio | 10-Q: Quarterly report
Cabaletta Bio Reveals Insights in Updated Corporate Presentation